This is a dilutive capital raise for a pre-revenue clinical-stage biotech with a going-concern warning. The ~11% increase in share count is material for a $34M market cap company. Monitor for further cash burn and the need for additional financing within the next 12 months. The common warrants at $1.75 represent overhang but are out of the money at the offering price.
Price Chart
Executive Summary
NanoViricides is raising approximately $3.5M in net proceeds via a registered direct offering of 2,416,339 shares of common stock at $1.53/share, pre-funded warrants for 100,000 shares, and common warrants for 2,516,339 shares at $1.75. The company has no revenue, an accumulated deficit of ~$149M, and an auditor's going-concern qualification, making this a dilutive capital raise to fund operations and Phase II trials. The offering increases total shares outstanding by ~11% immediately, with further dilution potential from the common warrants.
Key Facts
- Offering of 2,416,339 shares at $1.53/share, plus pre-funded warrants for 100,000 shares and common warrants for 2,516,339 shares at $1.75.
- Net proceeds to the company are approximately $3.5M after placement agent fees and expenses.
- Common stock outstanding immediately after the offering will be 25,499,155 shares, up from 22,982,816.
- Company has no revenue, an accumulated deficit of ~$149M as of June 30, 2025, and an auditor's going-concern qualification.
- Cash and cash equivalents were ~$1.6M as of June 30, 2025; management states existing resources are insufficient for 12 months of operations.
- New investors face immediate dilution of $1.02 per share based on net tangible book value.
- CEO and TheraCour are subject to a 30-day lock-up; company has a 60-day standstill on further equity issuance.
- Common warrants are exercisable at $1.75 (vs. $1.53 offering price) starting six months from issuance, expiring in 5.5 years.
Financial Impact
~$3.5M net proceeds raised, representing ~11% immediate dilution to existing shareholders with additional potential dilution from 2.5M common warrants
Risk Factors
- Going-concern risk: company may not have sufficient funds for 12 months of operations.
- Significant dilution: ~11% immediate share increase plus potential dilution from 2.5M common warrants.
- No revenue or approved products; clinical-stage pipeline with high execution risk.
- Reliance on TheraCour for core technology and product development.
- Potential delisting risk from NYSE American if continued listing standards are not met.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-086797 |
| Document: 0001104659-26-086797-index-headers.html | 0001104659-26-086797 |
| Document: 0001104659-26-086797-index.html | 0001104659-26-086797 |
| Document: 0001104659-26-086797.txt | 0001104659-26-086797 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 424B5 | $1.51 | awaiting T+60 | — | $1.40 (−7.28%) |
Oct 8, 2026 18d ago | DEF 14A | $1.31 | awaiting T+60 | — | $1.40 (+6.87%) |
Jul 27, 2026 13w ago | 424B5 | $1.54 $1.48 | ▲ +3.90% | ▲ +7.95% | $1.40 (+9.09%) |
Jul 27, 2026 13w ago | 424B5 | $1.54 $1.48 | ▼ −3.90% | ▼ −7.95% | $1.40 (−9.09%) |
Jun 29, 2026 17w ago | EFFECT | $1.37 $1.51 | ▼ −10.22% | ▼ −6.60% | $1.40 (−2.19%) |
Jun 16, 2026 18w ago | EFFECT | $1.36 $1.02 | ▼ −25.00% | ▼ −26.86% | $1.40 (+2.94%) |
Jun 15, 2026 19w ago | S-3 | $1.36 $1.02 | ▼ −25.00% | ▼ −26.86% | $1.40 (+2.94%) |
Jun 5, 2026 20w ago | S-3 | $1.43 $1.17 | ▲ +18.18% | ▲ +21.69% | $1.40 (+2.10%) |
May 18, 2026 23w ago | 424B5 | $1.51 $1.37 | ▲ +9.27% | ▲ +14.12% | $1.40 (+7.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers